White House to unveil ‘TrumpRX’ drug-buying website, announce Pfizer lowering prices in US

WASHINGTON — President Trump will announce the launch of a new website Tuesday giving Americans the chance to buy drugs directly from the government rather than going through insurance, a White House source told The Post.

The direct-to-consumer website — “TrumpRx” — will be coupled with an announcement that Pfizer plans to lower its prices on some medications distributed in the US, press secretary Karoline Leavitt announced on X.

“I think it’s one of the biggest things that we’ll do. We’ll be reducing drug prices by 100% in some cases, 300% or more,” Trump told reporters on the South Lawn of the White House ahead of the announcement.

The news was first reported by the Wall Street Journal.

The TrumpRx site will offer drugs at a lower rate negotiated directly by the government, though it was not immediately clear what medications would be available.

“President Trump is doing more to lower healthcare costs than anyone else in Washington, D.C.,” White House spokesman Kush Desai said in a statement.

“While Democrats are threatening to shut down the federal government to subsidize health care for illegal aliens, President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans. Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.”

The drug announcement comes one day before Trump’s deadline for pharmaceutical companies to move their manufacturing operations to the US — or face a 100% tariff. 

“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump wrote on Truth Social last week.

Companies already building manufacturing sites in the US will not be subjected to the tariff.

The tariff will most likely impact smaller pharma companies who do not have facilities in the US, while larger ones may be spared.

Companies like Johnson & Johnson, Eli Lilly, Merck, AstraZeneca and Novo Nordisk already have manufacturing plants in the US.